These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17502122)

  • 41. Synthesis and biological activities of new furo[3,4-b]carbazoles: potential topoisomerase II inhibitors.
    Hajbi Y; Neagoie C; Biannic B; Chilloux A; Vedrenne E; Baldeyrou B; Bailly C; Mérour JY; Rosca S; Routier S; Lansiaux A
    Eur J Med Chem; 2010 Nov; 45(11):5428-37. PubMed ID: 20863598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A three-step synthesis from rebeccamycin of an efficient checkpoint kinase 1 inhibitor.
    Anizon F; Golsteyn RM; Léonce S; Pfeiffer B; Prudhomme M
    Eur J Med Chem; 2009 May; 44(5):2234-8. PubMed ID: 18602198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of selenophene derivatives as novel CHK1 inhibitors.
    Hong PC; Chen LJ; Lai TY; Yang HY; Chiang SJ; Lu YY; Tsai PK; Hsu HY; Wei WY; Liao CB
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5065-8. PubMed ID: 20674356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
    Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction of Benzo[c]carbazoles and Their Antitumor Derivatives through the Diels-Alder Reaction of 2-Alkenylindoles and Arynes.
    Sha F; Tao Y; Tang CY; Zhang F; Wu XY
    J Org Chem; 2015 Aug; 80(16):8122-33. PubMed ID: 26204058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of inhibitors of checkpoint kinase 1 through template screening.
    Matthews TP; Klair S; Burns S; Boxall K; Cherry M; Fisher M; Westwood IM; Walton MI; McHardy T; Cheung KM; Van Montfort R; Williams D; Aherne GW; Garrett MD; Reader J; Collins I
    J Med Chem; 2009 Aug; 52(15):4810-9. PubMed ID: 19572549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
    Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
    J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An efficient synthesis of indolo[3,2-a]carbazoles via the novel acid catalyzed reaction of indoles and diaryl-1,2-diones.
    Nair V; Nandialath V; Abhilash KG; Suresh E
    Org Biomol Chem; 2008 May; 6(10):1738-42. PubMed ID: 18452007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of Cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA damage kinase, checkpoint kinase 1.
    Perron-Sierra FM; Kucharkzyk N; Boucley C; Guyard-Daumas C; Sciberras S; Fouache C; Plantier S; Studeny A; Bossard C; Casara PJ; Golsteyn RM
    Anticancer Agents Med Chem; 2012 Mar; 12(3):194-201. PubMed ID: 22044003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clausine Z, a new carbazole alkaloid from Clausena excavata with inhibitory activity on CDK5.
    Potterat O; Puder C; Bolek W; Wagner K; Ke C; Ye Y; Gillardon F
    Pharmazie; 2005 Aug; 60(8):637-9. PubMed ID: 16124414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological potential of carbazole derivatives.
    Głuszyńska A
    Eur J Med Chem; 2015 Apr; 94():405-26. PubMed ID: 25794500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
    Rivalle C; Wendling F; Tambourin P; Lhoste JM; Bisagni E; Chermann JC
    J Med Chem; 1983 Feb; 26(2):181-5. PubMed ID: 6827534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.
    Tao ZF; Li G; Tong Y; Chen Z; Merta P; Kovar P; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4308-15. PubMed ID: 17544271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-vitro antiproliferative activities and kinase inhibitory potencies of glycosyl-isoindigo derivatives.
    Sassatelli M; Bouchikhi F; Aboab B; Anizon F; Fabbro D; Prudhomme M; Moreau P
    Anticancer Drugs; 2007 Oct; 18(9):1069-74. PubMed ID: 17704657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and mixed lineage kinase activity of pyrrolocarbazole and isoindolone analogs of (+)K-252a.
    Hudkins RL; Johnson NW; Angeles TS; Gessner GW; Mallamo JP
    J Med Chem; 2007 Feb; 50(3):433-41. PubMed ID: 17266195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
    Brnardic EJ; Garbaccio RM; Fraley ME; Tasber ES; Steen JT; Arrington KL; Dudkin VY; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5989-94. PubMed ID: 17804227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase.
    Garbaccio RM; Huang S; Tasber ES; Fraley ME; Yan Y; Munshi S; Ikuta M; Kuo L; Kreatsoulas C; Stirdivant S; Drakas B; Rickert K; Walsh ES; Hamilton KA; Buser CA; Hardwick J; Mao X; Beck SC; Abrams MT; Tao W; Lobell R; Sepp-Lorenzino L; Hartman GD
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6280-5. PubMed ID: 17900896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis of pyrazolo[4,3-a]phenanthridines, a new scaffold for Pim kinase inhibition.
    Suchaud V; Gavara L; Giraud F; Nauton L; Théry V; Anizon F; Moreau P
    Bioorg Med Chem; 2014 Sep; 22(17):4704-10. PubMed ID: 25087047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
    Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.